CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 101 enrolled
Drug / intervention
OPC-249drug
Likely dose
OPC-249 30 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00504426
NCT00504426Phase 2Completed
CompareCT.gov

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Jul 20, 2007·Updated Jan 30, 2014

In Brief

A Phase 2 clinical trial evaluating OPC-249 for Pain Due to Osteoporosis. Completed, enrolled 101 participants across 5 sites.

Detailed Summary

The purpose of this study is to examine the efficacy and safety of OPC-249 by once daily inhalation at 0 (placebo), 30, 60 or 120 IU for 4 weeks in patients with pain due to osteoporosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain Due to Osteoporosis
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 20, 2007
Enrollment StartJul 1, 2007
Primary CompletionJul 1, 2008
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.9 years ago

Interventions

OPC-249drug

1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)